首页> 外文期刊>Pharmacology & Pharmacy >Aqueous Solubility Enhancement of Mirtazapine: Effect of Cosolvent and Surfactant
【24h】

Aqueous Solubility Enhancement of Mirtazapine: Effect of Cosolvent and Surfactant

机译:米氮平的水溶性提高:助溶剂和表面活性剂的作用

获取原文
           

摘要

The poor aqueous solubility of drugs is a challenging problem faced by pharmaceutical scientists in drug formulation. Cosolvency and micellization techniques have been severally used to enhance the solubility of poorly aqueous soluble drugs. Mirtazapine, a tetracyclic antidepressant used for the treatment of moderate to severe depression and anxiety, has very poor aqueous solubility. The objective of the study was to investigate the effect of solubilizing agents (cosolvents and surfactants) on the aqueous solubility of mirtazapine while envisaging that any significant improvement in its aqueous solubility could contribute towards alleviating the withdrawal symptoms often associated with the drug. The solubility of mirtazapine was determined at room temperature in aqueous mixtures of cosolvents (propylene glycol and polyethylene glycol 400) and surfactants (polysorbate 20, polysorbate 80 and sodium lauryl sulfate). An exponential increase in mirtazapine solubility was observed when total drug solubility in water-cosolvent system was plotted against cosolvent fraction volume. Polyethylene glycol 400 gave larger solubilization capacity (σ) when compared to propylene glycol. With the surfactants, linear relationship between the total solubility of the drug in water-surfactant mixtures and surfactant concentration was noted. Sodium lauryl sulfate showed the largest solubilization power (k) when compared to the nonionic surfactants (polysorbate 20 and polysorbate 80 respectively). A linear relationship between standard free energy and partition coefficient was also observed. The result of the study shows that aqueous solubility of mirtazapine is significantly improved by cosolvency and micellization and therefore there exists the possibility of improving the withdrawal symptoms often experienced with the drug. It also suggests that large free energy is required for drugs with high partition coefficients to permeate the biological membrane.
机译:药物的水溶性差是药物科学家在药物制剂中面临的挑战性问题。溶解度和胶束化技术已被多次用于增强水溶性差的药物的溶解度。米氮平是一种用于治疗中度至重度抑郁症和焦虑症的四环抗抑郁药,其水溶性非常差。该研究的目的是研究增溶剂(助溶剂和表面活性剂)对米氮平的水溶性的影响,同时设想其水溶性的任何显着改善可有助于缓解通常与药物有关的戒断症状。米氮平的溶解度是在室温下在助溶剂(丙二醇和聚乙二醇400)和表面活性剂(聚山梨酯20,聚山梨酯80和月桂基硫酸钠)的水性混合物中测定的。当将水-助溶剂系统中的总药物溶解度与助溶剂馏分体积作图时,观察到米氮平的溶解度呈指数增加。与丙二醇相比,聚乙二醇400具有更大的增溶能力(σ)。使用表面活性剂,注意到药物在水表面活性剂混合物中的总溶解度与表面活性剂浓度之间的线性关系。与非离子表面活性剂(分别为聚山梨酯20和聚山梨酯80)相比,十二烷基硫酸钠显示出最大的增溶能力(k)。还观察到标准自由能和分配系数之间的线性关系。研究结果表明,米氮平的水溶性可通过共溶和胶束化得到显着改善,因此存在改善该药常出现的戒断症状的可能性。这也表明具有高分配系数的药物需要大量的自由能才能渗透到生物膜中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号